Inhibition of matrix-induced bone differentiation by advanced glycation end-products in rats

Y. Fong, D. Edelstein, E. A. Wang, M. Brownlee

Research output: Contribution to journalArticle

24 Citations (Scopus)

Abstract

Glycation of long-lived proteins is an inevitable consequence of aging that is accelerated in patients with diabetes mellitus. Treatment of demineralized bone matrix particles from 35-week-old normal Long-Evans rats with glycolaldehyde, a precursor of advanced glycation end-products, was used to assess the effects of bone-matrix glycation on the process of bone differentiation. Matrix was incubated in phosphate buffered saline alone, phosphate buffered saline containing glycolaldehyde, glycolaldehyde plus the advanced glycation product-inhibitor aminoguanidine, or glycolaldehyde plus the advanced glycation product-inhibitor sodium cyanoborohydride. Glycolaldehyde increased the matrix advanced glycation product content as measured by specific fluorescence more than two-fold, while inhibiting bone differentiation more than 90 % as measured by in vivo 45CaCl2 uptake, alkaline phosphatase levels, and histology. In contrast, simultaneous incubation with the advanced glycation product-inhibitor aminoguanidine or sodium cyanoborohydride not only reduced fluorescence to normal, but also restored bone differentiation. Furthermore, the inhibition of bone differentiation by glycolaldehyde was not reversed by subsequent application of recombinant bone morphogenetic protein-2. These observations suggest that formation of advanced glycation products on bone matrix alters its ability to induce bone formation, and probably involves alterations of binding sites for extractable proteins with direct bone inductive properties such as bone morphogenetic protein-2. Decreased bone formation associated with aging and diabetes may result, in part, from advanced glycation product formation on matrix proteins.

Original languageEnglish (US)
Pages (from-to)802-807
Number of pages6
JournalDiabetologia
Volume36
Issue number9
DOIs
StatePublished - Sep 1993

Fingerprint

Advanced Glycosylation End Products
Bone Matrix
Bone and Bones
Bone Morphogenetic Protein 2
Osteogenesis
Fluorescence
Phosphates
Long Evans Rats
Proteins
Recombinant Proteins
Alkaline Phosphatase
glycolaldehyde
Histology
Diabetes Mellitus
Binding Sites

Keywords

  • Aging
  • bone differentiation
  • bone healing
  • bone matrix
  • diabetes mellitus

ASJC Scopus subject areas

  • Internal Medicine
  • Endocrinology, Diabetes and Metabolism

Cite this

Inhibition of matrix-induced bone differentiation by advanced glycation end-products in rats. / Fong, Y.; Edelstein, D.; Wang, E. A.; Brownlee, M.

In: Diabetologia, Vol. 36, No. 9, 09.1993, p. 802-807.

Research output: Contribution to journalArticle

Fong, Y. ; Edelstein, D. ; Wang, E. A. ; Brownlee, M. / Inhibition of matrix-induced bone differentiation by advanced glycation end-products in rats. In: Diabetologia. 1993 ; Vol. 36, No. 9. pp. 802-807.
@article{2736de27c750492a8c398eec9ff14ca2,
title = "Inhibition of matrix-induced bone differentiation by advanced glycation end-products in rats",
abstract = "Glycation of long-lived proteins is an inevitable consequence of aging that is accelerated in patients with diabetes mellitus. Treatment of demineralized bone matrix particles from 35-week-old normal Long-Evans rats with glycolaldehyde, a precursor of advanced glycation end-products, was used to assess the effects of bone-matrix glycation on the process of bone differentiation. Matrix was incubated in phosphate buffered saline alone, phosphate buffered saline containing glycolaldehyde, glycolaldehyde plus the advanced glycation product-inhibitor aminoguanidine, or glycolaldehyde plus the advanced glycation product-inhibitor sodium cyanoborohydride. Glycolaldehyde increased the matrix advanced glycation product content as measured by specific fluorescence more than two-fold, while inhibiting bone differentiation more than 90 {\%} as measured by in vivo 45CaCl2 uptake, alkaline phosphatase levels, and histology. In contrast, simultaneous incubation with the advanced glycation product-inhibitor aminoguanidine or sodium cyanoborohydride not only reduced fluorescence to normal, but also restored bone differentiation. Furthermore, the inhibition of bone differentiation by glycolaldehyde was not reversed by subsequent application of recombinant bone morphogenetic protein-2. These observations suggest that formation of advanced glycation products on bone matrix alters its ability to induce bone formation, and probably involves alterations of binding sites for extractable proteins with direct bone inductive properties such as bone morphogenetic protein-2. Decreased bone formation associated with aging and diabetes may result, in part, from advanced glycation product formation on matrix proteins.",
keywords = "Aging, bone differentiation, bone healing, bone matrix, diabetes mellitus",
author = "Y. Fong and D. Edelstein and Wang, {E. A.} and M. Brownlee",
year = "1993",
month = "9",
doi = "10.1007/BF00400353",
language = "English (US)",
volume = "36",
pages = "802--807",
journal = "Diabetologia",
issn = "0012-186X",
publisher = "Springer Verlag",
number = "9",

}

TY - JOUR

T1 - Inhibition of matrix-induced bone differentiation by advanced glycation end-products in rats

AU - Fong, Y.

AU - Edelstein, D.

AU - Wang, E. A.

AU - Brownlee, M.

PY - 1993/9

Y1 - 1993/9

N2 - Glycation of long-lived proteins is an inevitable consequence of aging that is accelerated in patients with diabetes mellitus. Treatment of demineralized bone matrix particles from 35-week-old normal Long-Evans rats with glycolaldehyde, a precursor of advanced glycation end-products, was used to assess the effects of bone-matrix glycation on the process of bone differentiation. Matrix was incubated in phosphate buffered saline alone, phosphate buffered saline containing glycolaldehyde, glycolaldehyde plus the advanced glycation product-inhibitor aminoguanidine, or glycolaldehyde plus the advanced glycation product-inhibitor sodium cyanoborohydride. Glycolaldehyde increased the matrix advanced glycation product content as measured by specific fluorescence more than two-fold, while inhibiting bone differentiation more than 90 % as measured by in vivo 45CaCl2 uptake, alkaline phosphatase levels, and histology. In contrast, simultaneous incubation with the advanced glycation product-inhibitor aminoguanidine or sodium cyanoborohydride not only reduced fluorescence to normal, but also restored bone differentiation. Furthermore, the inhibition of bone differentiation by glycolaldehyde was not reversed by subsequent application of recombinant bone morphogenetic protein-2. These observations suggest that formation of advanced glycation products on bone matrix alters its ability to induce bone formation, and probably involves alterations of binding sites for extractable proteins with direct bone inductive properties such as bone morphogenetic protein-2. Decreased bone formation associated with aging and diabetes may result, in part, from advanced glycation product formation on matrix proteins.

AB - Glycation of long-lived proteins is an inevitable consequence of aging that is accelerated in patients with diabetes mellitus. Treatment of demineralized bone matrix particles from 35-week-old normal Long-Evans rats with glycolaldehyde, a precursor of advanced glycation end-products, was used to assess the effects of bone-matrix glycation on the process of bone differentiation. Matrix was incubated in phosphate buffered saline alone, phosphate buffered saline containing glycolaldehyde, glycolaldehyde plus the advanced glycation product-inhibitor aminoguanidine, or glycolaldehyde plus the advanced glycation product-inhibitor sodium cyanoborohydride. Glycolaldehyde increased the matrix advanced glycation product content as measured by specific fluorescence more than two-fold, while inhibiting bone differentiation more than 90 % as measured by in vivo 45CaCl2 uptake, alkaline phosphatase levels, and histology. In contrast, simultaneous incubation with the advanced glycation product-inhibitor aminoguanidine or sodium cyanoborohydride not only reduced fluorescence to normal, but also restored bone differentiation. Furthermore, the inhibition of bone differentiation by glycolaldehyde was not reversed by subsequent application of recombinant bone morphogenetic protein-2. These observations suggest that formation of advanced glycation products on bone matrix alters its ability to induce bone formation, and probably involves alterations of binding sites for extractable proteins with direct bone inductive properties such as bone morphogenetic protein-2. Decreased bone formation associated with aging and diabetes may result, in part, from advanced glycation product formation on matrix proteins.

KW - Aging

KW - bone differentiation

KW - bone healing

KW - bone matrix

KW - diabetes mellitus

UR - http://www.scopus.com/inward/record.url?scp=0027305162&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027305162&partnerID=8YFLogxK

U2 - 10.1007/BF00400353

DO - 10.1007/BF00400353

M3 - Article

C2 - 8405750

AN - SCOPUS:0027305162

VL - 36

SP - 802

EP - 807

JO - Diabetologia

JF - Diabetologia

SN - 0012-186X

IS - 9

ER -